CONNECT WITH US
AI & Deeptech

AI & Deeptech

OpenAI acquires Orchestra Bio to build AI agents that speed up drug development

The Decoder logo

Published on

Add as a preferred source on Google
OpenAI acquires Orchestra Bio to build AI agents that speed up drug development

OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on average. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research.

The article OpenAI acquires Orchestra Bio to build AI agents that speed up drug development appeared first on The Decoder.



Source link
Related Topics:AI & Deeptech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.